ENTAEnanta Pharmaceuticals, Inc.
13.47USD-0.30%Mkt Cap: 392.32M $P/E: —3d ago
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap392.32M $
Enterprise Value374.95M $
Revenue (TTM)65.26M $
Gross Profit65.26M $
Net Income (TTM)-81.89M $
Revenue/Share2.411 USD
Last Price13.47 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees120
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS29251M1062
Valuation
P/E (Trailing)—
P/E (Forward)-5.64
PEG—
EV/EBITDA-6.97
EV/Revenue5.75
P/S5.86
P/B3.78
EPS (TTM)-2.36
EPS (Forward)-2.33
52W Range
7.05064% of range17.15
52W High17.15 USD
52W Low7.050 USD
Profitability
Gross Margin100.00%
Oper. Margin-120.04%
EBITDA Margin-82.47%
Profit Margin-125.36%
ROE-126.53%
ROA-29.17%
Growth
Revenue Growth-21.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.27M $
CapEx (TTM)12.90M $
FCF Margin-34.72%
FCF Yield-5.78%
Net Debt-7.47M $
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity0.89
Current Ratio3.76
Quick Ratio3.62
Book Value/Sh3.471 USD
Cash/Share6.507 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.17 USD
Upside (mean)+57.1%
Target Range19.00 USD – 28.00 USD
$19.00+57.1% to mean$28.00
# Analysts6
Ownership
Shares Out.29.13M
Float22.51M
Insiders4.67%
Institutions94.33%
Short Interest
Short Ratio14.9d
Short % Float10.65%
Short % Out.8.90%
Shares Short2.59M
Short (prev mo.)2.58M
Technical
SMA 5013.30 (+1.3%)
SMA 20013.48 (-0.1%)
Beta0.93
S&P 52W Chg18.16%
Avg Vol (30d)164.02K
Avg Vol (10d)190.03K
Technical Indicators
RSI (14)52.5
MACD0.0274
MACD Signal0.0061
MACD Hist.+0.0213
BB Upper13.95 USD
BB Middle13.15 USD
BB Lower12.34 USD
BB Width12.22%
ATR (14)0.6176 USD
Vol Ratio (20d)1.70x